Proteomics in atherothrombosis: A future perspective

Expert Review of Proteomics

Volumn 4, Issue 2, 2007, Pages 249-260

  Martín Ventura, Jose Luis ^b,c,d,e   Blanco Colio, Luis Miguel ^b   Tunon, Jose ^b   Gomez Guerrero, Carmen ^b   Michel, Jean Baptiste ^c,d,e   Meilhac, Olivier ^c,d,e   Egido, Jesus ^a  

^a Hospital UniversitarioFundación Jiménez Díaz   (Spain)

^b UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^c INSERM   (France)

^d UNIVERSITÉ PARIS DESCARTES   (France)

^e BICHAT HOSPITAL   (France)

Author keywords

Array based technique; Atherosclerosis; Cardiovascular biomarker; Imaging mass spectrometry; Peptidomics; Population proteomics; Proteomics

Indexed keywords

BIOLOGICAL MARKER; PLASMA PROTEIN; TROPONIN;

ANALYTIC METHOD; ARTERY THROMBOSIS; ATHEROSCLEROSIS; BLOOD SAMPLING; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DIAGNOSTIC VALUE; GENOMICS; HUMAN; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; METABOLOMICS; PEPTIDOMICS; PROTEIN EXPRESSION; PROTEOMICS; REVIEW; RISK ASSESSMENT; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; TISSUE MICROARRAY; TWO DIMENSIONAL ELECTROPHORESIS;

ATHEROSCLEROSIS; BIOLOGICAL MARKERS; BLOOD PROTEINS; ENDOTHELIUM, VASCULAR; HUMANS; PROTEINS; PROTEOMICS; THROMBOSIS;

EID: 34247153866     PISSN: 14789450     EISSN: 17448387     Source Type: Journal    
DOI: 10.1586/14789450.4.2.249     Document Type: Review

References (71)

1. Murray CJ, Lopez AD. Mortality by cause for eight regions of the world: global burden of disease study. Lancet 349, 1269-1276 (1997).
2. Steinberg D. Atherogenesis in perspective: hypercholesteolemia and inflammation as partner in crime. Nat. Med. 11, 1211-1217 (2002).
3. Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and acute coronary syndromes. N. Engl. J. Med. 326, 242-250 (1992).
4. Libby P, Aikawa M. Stabilization of atherosclerotic plaques: new mechanisms and clinical targets. Nat. Med. 11, 1257-1262 (2002).
5. Glass CK, Witztum, JL. Atherosclerosis: the road ahead. Cell 104, 503-516 (2001).
6. Li AC, Glass CK. The macrophage foam cell as a target for therapeutic intervention. Nat. Med. 11, 1235-1242 (2002).
7. Geng YJ, Libby P. Progression of atheroma: a struggle between death and procreation. Arterioscler. Thromb. Vasc. Biol. 22, 1370-1380 (2002).
8. Galis ZS, Sukhova GK, Lark MW, Libby P. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J. Clin. Invest. 94, 2493-2503 (1994).
9. Leclercq A, Houard X, Loyau S et al. Topology of protease activities reflects atherothrombotic plaque complexity. Atherosclerosis 191(1), 1-10 (2007).
10. Virmani R, Kolodgie FD, Burke AP et al. Atherosclerotic plaque progression and vulnerability to rupture: angiogenesis as a source of intraplaque hemorrhage. Arterioscler. Thromb. Vasc. Biol. 25, 2054-2061 (2005). • Discusses the potential role of intraplaque vasa vasorum in lesion instability as it relates to plaque rupture.
11. Takaya N, Yuan C, Chu B et al. Presence of intraplaque hemorrhage stimulates progression of carotid atherosclerotic plaques: a high-resolution magnetic resonance imaging study. Circulation 111, 2768-2775 (2005).
12. Houard X, Leclercq A, Fontaine V et al. Retention and activation of blood-borne proteases in the arterial wall: implications for atherothrombosis. J. Am. Coll. Cardiol. 48, A3-A9 (2006).
13. Moreno PR, Purushothaman KR, Sirol M, Levy AP, Fuster V. Neovascularization in human atherosclerosis. Circulation 113, 2245-2252 (2006).
14. Vivanco F, Martin-Ventura JL, Duran MC et al. Quest for novel cardiovascular biomarkers by proteomic analysis. J. Proteome Res. 4, 1181-1191 (2005).
15. Tsimikas S, Willerson JT, Ridker PM. C-reactive protein and other emerging blood biomarkers to optimize risk stratification of vulnerable patients. J. Am. Coll. Cardiol. 47, C19-C31 (2006).
16. Danesh J, Wheeler JG, Hirschfield GM et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N. Engl. J. Med. 350, 1387-1397 (2004).
17. Sidney C, Smith J, Anderson JL et al. CDC/AHA Workshop on markers of inflammation and cardiovascular disease application to clinical and public health practice: report from the Clinical Practice Discussion Group. Circulation 110, e550-e555 (2004).
18. Anderson NL, Polanski M, Pieper R et al. The human plasma proteome: a nonredundant list developed by combination of four separate sources. Mol. Cell. Proteomics 3, 311-326 (2004).
19. Martin-Ventura JL, Duran MC, Blanco-Colio LM et al. Identification by a differential proteomic approach of heat shock protein 27 as a potential marker of atherosclerosis. Circulation 110, 2216-2219 (2004).
20. Arrell DK, Elliott ST, Kane LA et al. Proteomic analysis of pharmacological preconditioning: novel protein targets converge to mitochondrial metabolism pathways. Circ. Res. 99, 706-714 (2006).
21. Gallego-Delgado J, Lazaro A, Osende JI et al. Comparison of the protein profile of established and regressed hypertension-induced left ventricular hypertrophy. J. Proteome Res. 5, 404-413 (2006).
22. Dohke T, Wada A, Isono T et al. Proteomic analysis reveals significant alternations of cardiac small heat shock protein expression in congestive heart failure. J. Card. Fail. 12, 77-84 (2006).
23. De Souza AI, Wait R, Mitchell AG, Banner NR, Dunn MJ, Rose ML. Heat shock protein 27 is associated with freedom from graft vasculopathy after human cardiac transplantation. Circ. Res. 97, 192-198 (2005).
24. Duran MC, Mas S, Martin-Ventura JL et al. Proteomic analysis of human vessels: Application to the atherosclerotic plaques. Proteomics 3, 973-978 (2003).
25. Duran MC, Martin-Ventura JL, Mohammed S et al. Atorvastatin modulates the profile of proteins released by human atherosclerotic plaques. Eur. J. Pharmacol. (2007) (In Press)
26. Blanco-Colio LM, Martin-Ventura JL, Munoz-Garcia B et al. Identification of soluble tumor necrosis factor-like weak inducer of apoptosis (sTWEAK) as a possible biomarker of subclinical atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 27(4), 916-922 (2007).
27. Blanco-Colio LM, Martin-Ventura JL, Vivanco F, Michel JB, Meilhac O, Egido J. Biology of atherosclerotic plaques: what we are learning from proteomic analysis. Cardiovasc. Res. 72, 18-29 (2006).
28. Mockel M, Muller R, Vollert JO et al. Role of N-terminal pro-B-type natriuretic peptide in risk stratification in patients presenting in the emergency room. Clin. Chem. 51, 1624-1631 (2005).
29. Baxt WG, Shofer FS, Sites FD, Hollander JE. A neural network aid for the early diagnosis of cardiac ischemia in patients presenting to the emergency department with chest pain. Ann. Emerg. Med. 40, 575-583 (2002).
30. Vasan RS. Biomarkers of cardiovascular disease: molecular basis and practical considerations. Circulation 113, 2335-2362 (2006).
31. Arab S, Gramolini AO, Ping P et al. Cardiovascular proteomics: tools to develop novel biomarkers and potential applications. J. Am. Coll. Cardiol. 48, 1733-1741 (2006).
32. Parikh SV, de Lemos JA. Biomarkers in cardiovascular disease: integrating pathophysiology into clinical practice. Am. J. Med. Sci. 332, 186-197 (2006).
33. Gulmann C, Sheehan KM, Kay EW, Liotta LA, Petricoin EF III. Array-based proteomics: mapping of protein circuitries for diagnostics, prognostics, and therapy guidance in cancer. J. Pathol. 208, 595-606 (2006). • Interesting review on the novel array-based proteomics techniques.
34. Ahn EH, Kang DK, Chang SI, Kang CS, Han MH, Kang IC. Profiling of differential protein expression in angiogenin-induced HUVECs using antibody-arrayed ProteoChip. Proteomics 6, 1104-1109 (2006).
35. Gulmann C, Espina V, Petricoin E III et al. Proteomic analysis of apoptotic pathways reveals prognostic factors in follicular lymphoma. Clin. Cancer Res. 11, 5847-5855 (2005).
36. Tabibiazar R, Wagner RA, Deng A, Tsao PS, Quertermous T. Proteomic profiles of serum inflammatory markers accurately predict atherosclerosis in mice. Physiol. Genomics 25, 194-202 (2006).
37. Kunkel EJ, Dea M, Ebens A et al. An integrative biology approach for analysis of drug action in models of human vascular inflammation. FASEB J. 18, 1279-1281 (2004).
38. Kallioniemi OP, Wagner U, Kononen J, Sauter G. Tissue microarray technology for high-throughput molecular profiling of cancer. Hum. Mol. Genet. 10, 657-662 (2001).
39. Fleiner M, Kummer M, Mirlacher M et al. Arterial neovascularization and inflammation in vulnerable patients: early and late signs of symptomatic atherosclerosis. Circulation 110, 2843-2850 (2004).
40. Stoeckli M, Chaurand P, Hallahan DE, Caprioli RM. Imaging mass spectrometry: a new technology for the analysis of protein expression in mammalian tissues. Nat. Med. 7, 493-496 (2001).
41. Chaurand P, Norris JL, Cornett DS, Mobley JA, Caprioli RM. New developments in profiling and imaging of proteins from tissue sections by MALDI mass spectrometry. Proteome Res. 5, 2889-2900 (2006).
42. Yanagisawa K, Shyr Y, Xu BJ et al. Proteomic patterns of tumour subsets in non-small-cell lung cancer. Lancet 362, 433-439 (2003).
43. Schwartz SA, Weil RJ, Johnson MD, Toms SA, Caprioli RM. Protein profiling in brain tumors using mass spectrometry: feasibility of a new technique for the analysis of protein expression. Clin. Cancer Res. 10, 981-987 (2004).
44. Bouamrani A, Ternier J, Ratel D et al. Direct-tissue SELDI-TOF mass spectrometry analysis: a new application for clinical proteomics. Clin. Chem. 52, 2103-2106 (2006).
45. Malmberg P, Borner K, Chen Y et al. Localization of lipids in the aortic wall with imaging TOF-SIMS. Biochim. Biophys. Acta 1771, 185-195 (2007).
46. Mas S, Touboul D, Brunelle A et al. Lipid cartography of atherosclerotic plaque by cluster-TOF-SIMS imaging. Analyst 132(1), 24-26 (2007).
47. Righetti PG, Castagna A, Antonioli P, Boschetti E. Prefractionation techniques in proteome analysis: the mining tools of the third millennium. Electrophoresis 26, 297-319 (2005).
48. Donahue MP, Rose K, Hochstrasser D et al. Discovery of proteins related to coronary artery disease using industrial-scale proteomics analysis of pooled plasma. Am. Heart J. 152, 478-485 (2006).
49. Granger J, Siddiqui J, Copeland S, Remick D. Albumin depletion of human plasma also removes low abundance proteins including the cytokines. Proteomics 5, 4713-4718 (2005).
50. Thulasiraman V, Lin S, Gheorghiu L et al. Reduction of the concentration difference of proteins in biological liquids using a library of combinatorial ligands. Electrophoresis 26, 3561-3571 (2005).
51. Liotta LA, Petricoin EF. Serum peptidome for cancer detection: spinning biologic trash into diagnostic gold. J. Clin. Invest. 116, 26-30 (2006). •• Interesting brief commentary on the recent advances in the field of peptidomics.
52. Marshall J, Kupchak P, Zhu W et al. Processing of serum proteins underlies the mass spectral fingerprinting of myocardial infarction. J. Proteome Res. 2, 361-372 (2003).
53. Villanueva J, Shaffer DR, Philip J et al. Differential exoprotease activities confer tumor-specific serum peptidome patterns. J. Clin. Invest. 116, 271-284 (2006).
54. Diamandis EP. Point: proteomic patterns in biological fluids: do they represent the future of cancer diagnostics? Clin. Chem. 49, 1272-1275 (2003).
55. Hwang IK, Park SM, Kim SY, Lee ST. A proteomic approach to identify substrates of matrix metalloproteinase-14 in human plasma. Biochim. Biophys. Acta 1702, 79-87 (2004).
56. Lopez-Otin C, Overall CM. Protease degradomics: a new challenge for proteomics. Nat. Rev. Mol. Cell. Biol. 3, 509-519 (2002).
57. Martin-Ventura JL, Nicolas V, Houard X et al. Biological significance of decreased HSP27 in human atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 26, 1337-1343 (2006).
58. Martin-Ventura JL, Leclercq A, Blanco-Colio LM et al. Low plasma levels of HSP70 in patients with carotid atherosclerosis are associated with increased levels of proteolytic markers of neutrophil activation. Atherosclerosis (2006) (Epub ahead of print).
59. Nedelkov D, Kiernan UA, Niederkofler EE, Tubbs KA, Nelson RW. Population proteomics: the concept, attributes, and potential for cancer biomarker research. Mol. Cell. Proteomics 5, 1811-1818 (2006).
60. Peronnet E, Becquart L, Poirier F, Cubizolles M, Choquet-Kastylevsky G, Jolivet-Reynaud C. SELDI-TOF MS analysis of the cardiac troponin I forms present in plasma from patients with myocardial infarction. Proteomics 6, 6288-6299 (2006).
61. Kiernan UA, Nedelkov D, Nelson RW. Multiplexed mass spectrometric immunoassay in biomarker research: a novel approach to the determination of a myocardial infarct. J. Proteome Res. 5, 2928-2934 (2006). •• Interesting study designed to the discovery of novel biomarkers and to produce high-performance assays relevant to disease.
62. Bar-Or D, Thomas GW, Bar-Or R, Rael L, Winkler JV. Diagnostic potential of phosphorylated cardiac troponin I as a sensitive, cardiac-specific marker for early acute coronary syndrome: preliminary report. Clin. Chim. Acta 362, 65-70 (2005).
63. Nedelkov D, Kiernan UA, Niederkofler EE, Tubbs KA, Nelson RW. Investigating diversity in human plasma proteins. Proc. Natl Acad. Sci. USA 102, 0852-0857 (2005).
64. Anderson NL, Anderson NG. The human plasma proteome: history, character, and diagnostic prospects. Mol. Cell. Proteomics 1, 845-867 (2002).
65. Petricoin EF, Fishman DA, Conrads TP, Veenstra TD, Liotta LA. Lessons from Kitty Hawk: from feasibility to routine clinical use for the field of proteomic pattern diagnostics. Proteomics 4, 2357-2360 (2004).
66. Anderson L. Candidate-based proteomics in the search for biomarkers of cardiovascular disease. J. Physiol. 563, 23-60 (2005).
67. Rai AJ, Gelfand CA, Haywood BC et al. HUPO plasma proteome project specimen collection and handling: towards the standardization of parameters for plasma proteome samples. Proteomics 5, 3262-3277 (2005).
68. Rai AJ, Stemmer PM, Zhang Z et al. Analysis of Human Proteome Organization Plasma Proteome Project (HUPO PPP) reference specimens using surface enhanced laser desorption/ionization-time of flight (SELDI-TOF) mass spectrometry: multi-institution correlation of spectra and identification of biomarkers. Proteomics 5, 3467-3474 (2005).
69. Granger CB, Van Eyk JE, Mockrin SC, Anderson NL; National Heart, Lung, and Blood Institute Clinical Proteomics Working Group. National Heart, Lung, And Blood Institute Clinical Proteomics Working Group report. Circulation 109, 1697-1703 (2004).
70. Sabatine MS, Morrow DA, de Lemos JA et al. Multimarker approach to risk stratification in non-ST elevation acute coronary syndromes: simultaneous assessment of troponin I, C-reactive protein, and B-type natriuretic peptide. Circulation 105, 1760-1763 (2002).
71. Sabatine MS, Liu E, Morrow DA et al. Metabolomic identification of novel biomarkers of myocardial ischemia. Circulation 112, 3868-3875 (2005).